Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Clinical Trial Using Targeted Radiotherapy Delivered by an Yttrium-90 Radio-Labelled Anti-CD66 Monoclonal Antibody With High Dose Melphalan Compared to Melphalan Alone, Prior to Autologous Stem Cell Transplantation for Multiple Myeloma

NCT00637767 is registered in ClinicalTrials.gov with University of Southampton as lead sponsor.

NCT NCT00637767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00637767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Clinical Trial Using Targeted Radiotherapy Delivered by an Yttrium-90 Radio-Labelled Anti-CD66 Monoclonal Antibody With High Dose Melphalan Compared to Melphalan Alone, Prior to Autologous Stem Cell Transplantation for Multiple Myeloma
Lead sponsor
University of Southampton
Phase
Phase 2
Overall status
Terminated
Start date
December 1, 2007
Completion date
October 31, 2013
Enrollment
25 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm